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Background: The MagnaSafe Registry is a multicenter prospective study to determine the risk of MRI at 1.5T in 1500 patients with pacemakers 
(PM) and implantable cardioverter-defibrillators (ICD) who undergo clinically indicated non-thoracic imaging.
methods: Device interrogation was performed pre- and post-MRI using a standardized protocol. Primary endpoints were device failure, generator/
lead replacement, induced arrhythmia, loss of capture, or electrical reset. Secondary endpoints were clinically relevant device parameter changes.
results: From April 2009 to October 2012, 829 non-thoracic MRI studies were performed (617 PM, 212 ICD, 1620 leads) at 16 sites. No deaths, 
device failures, generator/lead replacements, losses of capture, or ventricular arrhythmias occurred. A decrease in battery voltage ≥0.04V occurred 
in 1% of PMs and 9% of ICDs. Pacing lead impedance changed ≥50Ω in 3% of PMs and 4% of ICDs. A decrease of ≥ 50% in P-wave amplitude 
occurred in 0.4% PM and 0.7% ICD leads. A decrease of ≥25% in R-wave amplitude occurred in 5% of PMs and 2% of ICDs. A decrease in R-wave 
amplitude ≥50% occurred in 1 ICD patient. A pacing threshold increase ≥0.5V at 0.4 ms occurred in 1% of PM leads and 2% of ICD leads. One 
or more clinically relevant device parameter changes occurred in 13% of PM and 28% of ICD cases, and 3% had >1 parameter change event. The 
frequency of a device parameter change event was 17% in those with and without a previous MRI. For PM cases, 1% had multiple parameter change 
events exclusive of battery voltage changes. In 9 PM cases with an impedance increase ≥50Ω, 1 (11%) had an additional change event, while 
in 29 cases with an impedance decrease ≥50Ω, 5 (17%) had an additional change event. However, a change in pacing lead impedance was not 
associated with changes in P/R wave voltage, pacing threshold or body mass index. In addition, right ventricular pacing lead age did not correlate 
with an increased risk of impedance change events.
conclusion: Preliminary results for the first 829 cases in MagnaSafe demonstrate no deaths, device failures, generator/lead replacements, 
ventricular arrhythmias, or losses of capture during non-thoracic MRI at 1.5T, and multiple parameter changes were infrequent.
